Article

Histologic analysis of acellular dermal matrix in the treatment of anal fistula in an animal model.

Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, PR China.
Journal of the American College of Surgeons (Impact Factor: 4.5). 06/2009; 208(6):1099-106. DOI: 10.1016/j.jamcollsurg.2009.02.052
Source: PubMed

ABSTRACT Human acellular dermal matrix (ADM) has been used successfully for the treatment of severe burns, ureter support, and abdominal wall reconstruction. This study was designed to evaluate the mechanism of ADM in the closure of anal fistula in an experimental porcine model.
The fistula-in-ano model was created in the porcine model and treated with ADM in 14 animals. Fistula specimens were obtained at hours 12 and 24 and on days 3, 7, 14, 28, 60. Hematoxylin and eosin staining, Masson trichrome staining, and immunohistochemical staining for alpha smooth muscle actin and matrix metalloproteinase 9 were performed.
The cell density increased from hour 12 to day 7 and decreased from day 7 to day 28 (p < 0.001). Mature vessels stained with alpha smooth muscle actin were identified at day 7. Alpha smooth muscle actin-positive myofibroblasts were found in clusters at the edge of the ADM at day 7. The density of vessels (p < 0.001) and myofibroblasts (p < 0.001) increased from day 7 to day 14. The density of matrix metalloproteinase 9 increased from hour 12 to day 7 and decreased from day 14 to day 60 (p < 0.001). Partially organized bundles of muscle were found by day 60.
We suggest that ADM is a reasonable new option for closure of anal fistulas. Anal fistulas begin to heal as early as 12 hours, and day 7 may be an important time point to judge whether the fistula healed preliminarily or not. The ability of ADM to become vascularized and remodeled by autologous cells may be advantageous for anal fistula healing.

1 Bookmark
 · 
136 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:  Ligation of the intersphincteric fistula tract and reinforcement with a bioprosthetic graft are two recently reported procedures that showed promise in the treatment of anal fistula. This study was undertaken to validate combining ligation of the intersphincteric fistula tract plus bioprosthetic anal fistula plug and report our preliminary results and experience. Methods:  21 patients with transsphincteric anal fistulae were treated with ligation of the intersphincteric fistula tract plus concurrent bioprosthetic plug of anal fistula. We evaluated healing time, fistula closure rate, and postoperative anal function according to the Wexner continence score. Results:  No mortality or major complications were observed. Median operative time was 20 (range 15-40) minutes. After a median follow-up of 14 (range 12-15) months, the overall success rate was 95% (20/21), with a median healing time of 2 (range 2-3) weeks for external anal fistula opening and 4 (range 3-7) weeks for intersphincteric groove incision. Only 1 (5%) patient reported rare incontinence for gas postoperatively (Wexner score 1). Conclusions:  Ligation of the intersphincteric fistula tract plus bioprosthetic anal fistula plug is an easy, safe, effective, and useful alternative in the management of anal fistula. Further randomized controlled studies are necessary to better evaluate long-term results. © 2012 The Authors Colorectal Disease © 2012 The Association of Coloproctology of Great Britain and Ireland.
    Colorectal Disease 10/2012; · 2.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract We report on a clinicopathologic study in an animal model of treatment with a new bioabsorbable polymer plug (BAPP). Over a 2-week period, 6 porcine models, which each had 4 anal fistulae, were created using Blake drains. The pigs were divided into 2 groups: the BAPP-treatment group (n = 12 fistulae) and the control group (n = 12 fistulae). Two weeks later, the pigs were humanely killed, and the perianal sites were excised and examined with gross and pathologic studies. Each fistula in the BAPP group was completely cured. In the pathologic study, the treatment sites had little disarray, few defects in the muscular layer, and small numbers of inflammatory cells. The control group had a significantly greater number of inflammatory cells and microabscesses than the BAPP group. The newly developed BAPP reduced the infection and induced good healing in anal fistulae. The BAPP may be a useful new device for the clinical treatment of anal fistulae.
    International surgery 98(2):122-128. · 0.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aim:  The mostly widely studied biomaterials for the sphincter sparing treatment of anal fistulas are fibrin glue and the anal fistula plug (AFP). However their overall mean clinical success is only 50-60%. As the understanding of anal fistula pathology, wound healing, and the host response to materials has improved, so new biological sphincter-sparing strategies have been developed. The aim of this review is to assess the safety and efficacy of these novel techniques. Method:  Pubmed, the Cochrane database, and EMBASE were independently searched. All studies that investigated the potential of a biomaterial (defined as any synthetic or biologically derived substance in contact with host tissue) to augment anal fistula healing without sphincter division were included. Studies solely describing the role of fibrin glue or the AFP were excluded. Data extraction included type of material, fistula aetiology, treatment of the primary tract, fistula healing, incontinence, duration of follow-up, and any specific complications. Results:  Twenty-three articles were finally selected for review. These included a variety of biological and synthetic systems that were employed to deliver selected components of the extracellular matrix, growth factors, cytokines, stem cells or drugs to the fistula tract. Conclusion:  To date no study matches fistulotomy with regard to long-term fistula eradication rates. This is likely due to implant extrusion, inadequate track preparation or an unsuitable material. Future techniques need to address all these issues to ensure success. Success should be validated by MRI or long-term follow up. © 2012 The Authors Colorectal Disease © 2012 The Association of Coloproctology of GreatBritain and Ireland.
    Colorectal Disease 08/2012; · 2.08 Impact Factor